Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients

Completed · Early Phase 1

Conditions studied: Postpartum Hemorrhage, Pregnancy Related, Hypocalcemia, Parturition Complication

In brief

Calcium is a life saving medicine in the care of parturients. It has many important uses including treatment of hypocalcemia, treatment of magnesium toxicity, prevention of hypocalcemia during blood transfusion (of citrate containing blood products), treatment of hyperkalemia, and others. Recent clinical trials also suggest that calcium given after cord clamping may decrease blood loss in patients undergoing cesarean delivery. 2 FDA approved forms of calcium can be given intravenously: calcium chloride and calcium gluconate. Over the last decade there have been times with drug shortages of either calcium chloride or calcium gluconate. So there have been and likely will continue to be times when one formulation or the other may not be adequately available. Despite the importance of calcium and the frequency in which it is used in parturients, there are no published studies in parturients to determine dose equivalence between calcium gluconate and calcium chloride. In this study the investigators will determine the population pharmacokinetics of calcium gluconate and calcium chloride in parturients and calculate the dose equivalent ratio the two drugs. This will help clinicians select appropriate doses of calcium and provide resilience to the drug supply chain in our era of frequent drug shortages.

Key facts

Study ID

NCT05973747

Run by

Stanford University

People needed

34

Starts

2023-08-19

Expected to finish

2023-12-15

Last updated by the study team

2024-04-11

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Pregnant female subjects delivering at the study institution via scheduled cesarean delivery at term (>=37 weeks gestation)

You may not qualify if…

• severe range blood pressure (BP >160/>110) within the 48 hours prior to delivery
• patient age <18 years or >45 years
• renal dysfunction with serum Cr > 1.0 mg/dL
• known history of congenital or acquired cardiac disease or history of arrhythmia
• patient taking digoxin
• patient currently taking a calcium channel blocker
• Weight <55kg or >100kg, or
• receiving magnesium infusion within 24 hours prior to or during cesarean delivery
• administration of intraoperative doses of calcium by the anesthesiology team for clinical indications

Where it is running

• Lucile Packard Children's Hospital — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.